Literature DB >> 3346570

Markers of cell-mediated immunity after vaccination with an inactivated, whole-cell Q fever vaccine.

A A Izzo1, B P Marmion, D A Worswick.   

Abstract

A clinical trial of Q fever vaccine in four South Australian abattoirs showed apparently complete protection against natural infection; however, only 50%-60% of vaccinees developed complement-fixing or immunofluorescent antibody after vaccination. Cell-mediated immunity to Coxiella burnetii antigens, as measured by an index of lymphoproliferative responses (LSI) of peripheral blood mononuclear cells, was therefore assessed. Eighty-five percent of 13 subjects with "low risk" of exposure to Q fever and with an initially negative LSI converted to a positive LSI after vaccination; conversion was noted nine to 13 days after vaccination, and positive values were obtained for at least 96 d. Only 35% of this group seroconverted. In a "high-risk" group (abattoir workers), higher rates of positive LSI (greater than 95%) and of antibody (50%-70%) were observed after vaccination; greater than 95% of vaccinees in this group, who had been vaccinated five years previously, had positive LSI values.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346570     DOI: 10.1093/infdis/157.4.781

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Chemokine Receptor 7 Is Essential for Coxiella burnetii Whole-Cell Vaccine-Induced Cellular Immunity but Dispensable for Vaccine-Mediated Protective Immunity.

Authors:  Chen Chen; Erin J van Schaik; Anthony E Gregory; Adam Vigil; Phillip L Felgner; Laura R Hendrix; Robert Faris; James E Samuel
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

2.  Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens.

Authors:  A A Izzo; B P Marmion; T Hackstadt
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Serological examination of human and animal sera from six countries of three continents for the presence of rickettsial antibodies.

Authors:  E Kovácová; W Sixl; D Stünzner; J Urvölgyi; J Kazár
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

4.  Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever.

Authors:  K E Russell-Lodrigue; G Q Zhang; D N McMurray; J E Samuel
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

5.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

6.  Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.

Authors:  L F Fries; D M Waag; J C Williams
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 7.  Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.

Authors:  Jeffrey G Shannon; Robert A Heinzen
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 8.  Q fever.

Authors:  L G Reimer
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Role for the CD28 molecule in the control of Coxiella burnetii infection.

Authors:  Amélie Honstettre; Soraya Meghari; Jacques A Nunès; Hubert Lepidi; Didier Raoult; Daniel Olive; Jean-Louis Mege
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Variation in interferon-gamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects.

Authors:  A A Izzo; B P Marmion
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.